Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Riociguat pediatric PAH open-label dose titration study
2014-003952-29Phase 3Completed
- Sponsor
- Bayer
- Start
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of riociguat in pulmonary arterial hypertension (PAH), sponsored by Bayer. Primary endpoint: Incidence of adverse events and serious adverse events. Started Jul 2015; status: completed.
02
Drugs
riociguat
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2014-003952-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003952-29.